10-Q: BiomX Inc. Pivots to Defense, Reports Q2 2026 Results

BiomX Inc. reports Q2 2026 results following a strategic shift to defense and security markets, with new revenue streams but continued operational losses and going concern doubts.

Summary

• BiomX Inc. has transitioned from its legacy biopharmaceutical business to focus on defense, security, and critical infrastructure technology markets.
• The company acquired ZorroNet and a controlling interest in DFSL in April 2026, contributing $332,000 in revenue for the first time in Q2 2026.
• Despite new revenue, the company reported a net loss of $3.85 million for Q2 2026 and $22.99 million for the first six months of 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to significant accumulated deficits and negative cash flows.
• The company is not in compliance with NYSE American continued listing standards regarding stockholders' equity and has a compliance plan through September 2027.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant ongoing losses, substantial doubt about the company's ability to continue as a going concern, and a low stock price impacting its ability to raise capital.

Positives

• Generated $332,000 in revenue for the first time in Q2 2026 from the newly acquired DFSL and ZorroNet subsidiaries.
• Successfully integrated DFSL and ZorroNet, which are now contributing to operations and revenue.
• Secured a framework supply agreement with Israel Railways for ZorroNet's AI-powered animal detection systems.
• Received acceptance of its compliance plan from NYSE Regulation, providing a period through September 25, 2027, to regain compliance with listing standards.
• Raised approximately $0.3 million in net proceeds from the at-the-market (ATM) offering program in Q2 2026, with an additional $2.4 million raised in July/August 2026.

Negatives

• Reported a net loss of $3.85 million for Q2 2026 and $22.99 million for the first six months of 2026.
• Has an accumulated deficit of $239.8 million as of June 30, 2026.
• Management believes current funds are sufficient for operations only for the next several months, raising substantial doubt about the ability to continue as a going concern.
• The company is not in compliance with NYSE American continued listing standards related to stockholders' equity.
• The low market price of its common stock limits its ability to raise capital through its ATM program and is substantially dilutive.

Risks

• Failure to regain compliance with NYSE American continued listing standards could lead to delisting, reducing liquidity and market price.
• The low market price of common stock may necessitate a reverse stock split to maintain listing.
• The company's ability to raise additional capital is subject to market conditions, stock price, and NYSE American rules.
• The ongoing insolvency proceedings of former subsidiary BiomX Ltd. and the anticipated Chapter 7 filing of Adaptive Phage Therapeutics, LLC present potential financial and operational uncertainties.
• Geopolitical and security instability in Israel and the surrounding region could adversely affect operations.

Future Outlook

The company expects to generate revenues from DFSL's LADAR systems, ZorroNet's AI platform, and X Security's distribution arrangements. However, it anticipates continued operating losses in the foreseeable future and plans to fund operations through equity issuances, debt, the Mandragola credit line, and cost-discipline measures. The ability to raise additional capital is subject to market conditions and NYSE American rules.

Management Comments

• Management believes that its current funds, together with the proceeds from the Companys ATM program, revenues expected to be generated by DFSL and ZorroNet will be sufficient to fund its operations only for the next several months following the issuance date of these financial statements.
• Management believes that there is substantial doubt as to our ability to continue as a going concern.
• We expect to continue to incur losses for the foreseeable future.

Industry Context

StockSavvy.ai notes that BiomX's strategic pivot into the defense, security, and critical infrastructure technology markets aligns with significant global trends driven by increasing geopolitical tensions, the proliferation of drone technology, and the need for advanced AI-driven surveillance and command-and-control systems. Competitors in these rapidly growing sectors include established defense contractors and specialized technology firms.

Comparison to Industry Standards

• The company's revenue generation of $332,000 in Q2 2026 from its new defense and security operations is nascent compared to established players in the defense technology sector.
• The significant net loss of $3.85 million for the quarter and the substantial accumulated deficit of $239.8 million highlight a financial performance that is not yet aligned with industry standards for profitable companies.
• The company's reliance on future capital raises and its ongoing compliance issues with NYSE listing standards are critical concerns when compared to companies with stable financial footing and established market positions.
• The successful pilot program for ZorroNet's animal detection system with Israel Railways, achieving a 98% success rate, demonstrates promising technology performance, though its commercial scalability against industry benchmarks is yet to be proven.

Corporate Governance

Legal Proceedings

• BiomX Ltd. is undergoing insolvency proceedings in Israel, with a trustee appointed on January 25, 2026.
• Adaptive Phage Therapeutics, LLC is a defendant in an action by The Emmes Company, LLC seeking approximately $333,000; APT is anticipated to file for Chapter 7 bankruptcy.

Related Party Transactions

• The company has a balance due to BiomX Ltd. of $1,254,000 as of June 30, 2026, related to the former subsidiary's insolvency proceedings.
• A credit line agreement exists with Mandragola Ltd., with $0 principal outstanding and $2,000,000 undrawn availability as of June 30, 2026.
• The company issued a convertible promissory note to Mandragola Ltd. for $3,000,000 in connection with the DFSL acquisition, which was satisfied by offset against a warrant exercise receivable.
• The company issued a warrant to Mandragola Ltd. to purchase 2,000,000 shares of common stock as consideration for the credit line.

Stakeholder Impact

• Shareholders face significant dilution from ongoing at-the-market (ATM) equity sales and potential future capital raises.
• The company's ability to continue as a going concern is uncertain, posing a risk to all stakeholders.
• Potential delisting from the NYSE American would reduce liquidity and market price, negatively impacting shareholders.
• Employees of the newly acquired defense businesses (DFSL and ZorroNet) are subject to the company's financial stability and strategic direction.
• Creditors of BiomX Ltd. may be impacted by the ongoing insolvency proceedings.

Next Steps

• Obtain stockholder approval at the August 25, 2026 meeting for stock issuances related to acquisitions and credit facilities.
• Regain compliance with NYSE American continued listing standards by September 25, 2027.
• Continue to integrate acquired subsidiaries DFSL and ZorroNet and expand their operations.
• Explore opportunities to commercialize the retained patent portfolio from the legacy biopharmaceutical business.
• File a Chapter 7 bankruptcy petition for Adaptive Phage Therapeutics, LLC.

Key Dates

Recommendation

The company has successfully pivoted to new, potentially high-growth markets in defense and security, evidenced by initial revenue generation and new contracts. However, significant financial challenges remain, including substantial losses, a going concern warning, and NYSE listing compliance issues. The stock's low price and dilutive capital raises present headwinds. A 'hold' recommendation reflects the speculative nature of the turnaround, balancing the potential upside from the new strategy against the considerable risks.

Keywords

Defense Technology, Security Systems, AI, LADAR, Counter-UAS, Critical Infrastructure, Business Combination, Financial Results